Vaxcyte’s pivotal OPUS-1 readout by the end of October is not a simple 31/31 pass/fail event. Management has already framed several expected serotype misses, so the stock debate is whether VAX-31 can deliver a meaningfully better-than-guided profile versus merely protecting adult value already embedded in PCVX’s valuation. Our latest report focuses on where the readout could surprise positively or negatively, how likely those outcomes are, how much they matter commercially, and how far the adult readout should be read through to the paediatric opportunity.